ADVERTISEMENT

marginal zone lymphoma

Research in Review

Novel Prognostic Index Designed for Patients With MZL

07/19/2017

JCP Editors

A new prognostic tool improves personalized treatment for patients with marginal zone lymphoma (MZL), according to recent research published in Blood (online July 2017;...

A new prognostic tool improves personalized treatment for patients with marginal zone lymphoma (MZL), according to recent research published in Blood (online July 2017;...

A new...

07/19/2017

Journal of Clinical Pathways

Research in Review

New Biomarker for Relapsed or Refractory MZL Identified

02/27/2017

JCP Editors

Patients with marginal zone lymphoma (MZL) who underwent prior therapy with an anti-CD20 antibody regimen may be treatable with a tyrosine kinase inhibitor approved for other blood cancers, according to research...

Patients with marginal zone lymphoma (MZL) who underwent prior therapy with an anti-CD20 antibody regimen may be treatable with a tyrosine kinase inhibitor approved for other blood cancers, according to research...

...

02/27/2017

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Advertisement

Advertisement

Advertisement

Upcoming Events

Dermatology Week

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

See Full Calendar

Advertisement

Advertisement